Conversations on Twitter :
@FierceBiotech: Wanted: Premier hepatitis C drug developer to partner with Vertex. More | Follow @FierceBiotech
@JohnCFierce: $1.2B in VC for biotech in Q3 not the best ever, but a whole lot more than we've been seeing--so I see it as a solid +. More | Follow @JohnCFierce
> Shares of Novavax ($NVAX) got a boost out of the news that two early-stage studies of its bird flu vaccine produced positive results. Story
> The EMA is recommending approval of Eli Lilly's ($LLY) Amyvid, a radioactive dye that can be used to help clinicians diagnose Alzheimer's. Story
> Chapel Hill, NC-based Cempra says it raised $25 million from the sale of shares. The biotech will earmark much of that to fund clinical trials. Release
> Histogen is touting early-stage evidence of efficacy for its "Hair Stimulating Complex." Release
Pharma News
@FiercePharma: More drug payment/pricing action in Greece. Some brand meds said to be struck from formulary. Article | Follow @FiercePharma
> Actavis CEO: Biosims market will be tough to crack. Report
> GSK CEO remains 'a huge bull on India.' Story
> EMA committee shoots down Vivus diet pill. Article
@FierceMedDev: VC investment in Q3 is way down for medical devices. More | Follow @FierceMedDev
@MarkHFierce: So what were the top med device VC deals in the 2012 third quarter? More | Follow @MarkHFierce
@DamianFierce: Steris is spending $110M on M&A to expand its surgical device capabilities. More | Follow @DamianFierce
> Complete Genomics scores patent win over Illumina. Story
> Study: To reduce heart disease risks, gastric banding beats drugs. News
> Sony slashes jobs on road to medical device focus. Item
And Finally… In a new study published in Nature, scientists point to mutations in neural stem cells as a likely new suspect involved in the hunt to determine what triggers Parkinson's disease. Story